WASHINGTON (February 11, 2025) – Children’s National Hospital announced today a new collaboration with Swiss medical device company Compremium AG to co-develop and commercialize innovative medical technologies designed specifically for pediatric patients. This first-of-its-kind agreement leverages the expertise of Children’s Nationalin pediatric healthcare innovation and Compremium’s non-invasive platform technology for diagnosing pressure-related conditions, accelerating advancements in pediatric medicine.
Diagnosing pressure-related conditions without complicated, invasive procedures has long been a challenge in the medical community. Compremium’s technology aims to transform the diagnosis of pressure physiologies, including venous pressure, intracranial pressure, and tissue pressure conditions with their non-invasive, point of care solution. Through this strategic collaboration, Children’s National will serve as the Pediatric Innovation Hub for Compremium, leading clinical studies, research projects, and commercialization efforts focused on non-invasive pressure monitoring and other breakthrough technologies.
“This partnership is a pivotal step in advancing pediatric-specific technologies to address critical gaps in care,” said Kolaleh Eskandanian, PhD, MBA, vice president and chief innovation officer at Children’s National. “Compremium’s non-invasive, real-time pressure monitoring technology not only has the potential to transform pediatric care, but also demonstrates how prioritizing pediatric innovation can pave the way for broader adoption and scalability to adult populations.”
Initial area of focus will be the use of Compremium’s technology in congenital heart disease (CHD) patients. Pediatric cardiologists require frequent, non-invasive monitoring of central venous pressure (CVP) — a crucial measure of blood volume returning to the heart and overall circulatory function. Improved CVP data could provide new insights into cardiovascular health, potentially leading to better interventions and preventing long-term complications such as developmental delays and learning difficulties, which affect approximately 33% of CHD patients nationwide.
“Non-invasive CVP monitoring for the pediatric population is the holy grail of cardiac care, a long-awaited advancement that has the potential to revolutionize care,” said Yves d'Udekem, MD, PhD, chief of the Division of Cardiac Surgery at Children's National. “Pediatric cardiac surgeons worldwide are eager for this breakthrough solution, which could transform how we monitor and treat cardiovascular patients. It’s exciting to see this innovation, and we are thrilled that Children’s National is leading the way in bringing it to children everywhere.”
“By integrating Compremium’s cutting-edge technology with AI-driven advancements, we aim to enhance accuracy, enable real-time data analysis, and provide predictive insights — critical capabilities for improving pediatric care” said Eskandanian. “Our pediatric providers are eager for innovative, child-friendly monitoring solutions that reduce the need for invasive procedures, and this collaboration is dedicated to making that a reality.”
For Compremium, this partnership marks an important milestone — its first major initiative in pediatric healthcare. “We are honored to collaborate with Children’s National Hospital,” said Vincent Baumann, CEO of Compremium AG. “This initiative allows us to accelerate and expand the clinical adoption of our solution, particularly for a vulnerable patient population.”
The collaboration agreement was led by Children’s National Innovation Ventures, the commercialization arm of Children’s National Hospital, dedicated to advancing regulated medical products that improve pediatric health. With a strong focus on industry partnerships, Innovation Ventures’ four core pillars focus on advancing pediatric-driven technologies, building strategic industry alliances, facilitating funding to de-risk and validate innovations, and managing intellectual property and licensing to drive commercialization — all by supporting both internal and external innovation to accelerate pediatric health solutions. Additionally, Innovation Ventures leads two federally-funded accelerator programs, supporting early-stage companies and academic teams in navigating regulatory, reimbursement, clinical, and commercialization pathways.
Media contact: Jhanae Kelley | jhanae@carbonaragroup.com | 713.524.8170 x111 | Cherri Carbonara | cherri@carbonaragroup.com | 713.524.8170 x114
###
About Children’s National Hospital
Children’s National Hospital, based in Washington, D.C., was established in 1870 to help every child grow up stronger. Today, it is one of the top 10 children’s hospitals in the nation and ranked in all specialties evaluated by U.S. News & World Report. Children’s National is transforming pediatric medicine for all children. The Children’s National Research & Innovation Campus opened in 2021, a first-of-its-kind pediatric hub dedicated to developing new and better ways to care for kids. Children’s National has been designated three times in a row as a Magnet® hospital, demonstrating the highest standards of nursing and patient care delivery. This pediatric academic health system offers expert care through a convenient, community-based primary care network and specialty care locations in the D.C. metropolitan area, including Maryland and Virginia. Children’s National is home to the Children’s National Research Institute and Sheikh Zayed Institute for Pediatric Surgical Innovation. It is recognized for its expertise and innovation in pediatric care and as a strong voice for children through advocacy at the local, regional and national levels. In 1987, Children’s National founded Safe Kids Worldwide, a non-profit dedicated to reducing unintentional injuries among children through comprehensive national and global education, research and advocacy. As a non-profit, Children's National relies on generous donors to help ensure that every child receives the care they need.
For more information, follow us on Facebook, Instagram and LinkedIn.
About Compremium AG
Compremium is a Swiss medical device company from Bern, Switzerland innovating in the diagnosis of pressure conditions in the human body. Compremium’s proprietary technology of combining ultrasound and pressure sensing was pioneered by Dr. Ulrich Baumann. The technology has been proven in over 40 clinical studies and has the potential to aid in diagnosing more than 30 medical indications and expects to make a significant impact in the diagnosis of a number of medical conditions. The lead indication for diagnosis of tissue related conditions is 510K-cleared by the FDA as of April 2023 and Compremium submits additional FDA and CE submissions in 2025. A prototype of the device has been in use by NASA on the International Space Station (ISS) for eight years.
For more information, follow us on LinkedIn, visit www.compremium.com or contact us: Aswin Bhuvanendran a.bhuvanendran@compremium.com / +1 301 617 89 84